Lipoprotein (a)

Česká verzia

Authors: L. Zlatohlávek; K. Zídková; M. Vráblík
Authors place of work: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2007; 53(4): 434-440
Category: Reviews

Summary

The lipids are transported by lipoproteins in the blood system. Lipoprotein (a) [Lp (a)] is a unique lipoprotein of the human plasma discovered by professor Berg in 1963. Lp (a) consists of apolipoprotein (a) and LDL particles (apolipoprotein B100). The level and size of Lp (a) are highly variable and largely determined heredity. Clinical studies on animal models have shown that elevated Lp (a) levels are linked with a higher risk of atherosclerosis, even though not all of the conclusions based on the studies that have been carried are convincing. Concentration over 35 mg/dl is considered to be a risk level. Surprisingly high Lp (a) levels in old age are associated with longevity. This may be explained by the physiological role of Lp (a) in tissue reparation, wound healing and anti-cancer effect.

Key words:
lipoprotein (a) – apolipoprotein (a) – atherosclerosis – ischemic heart disease

Zdroje

1. Berg KA. New serum type system in man: the Lp sytem. Acta Patol Microbial Scand 1963; 59: 369-382.

2. Morrisett JD. Lipoprotein (a): structure, metabolism and epidemiology, Plasma lipoproteins. Elservis Sc Publ 1987; 129-152.

3. Seegers W, Hirschholrn K, Burnett L et al. Basic enzymology of blood coagulation. Science 1965; 149: 303-304.

4. Dahlen G, Ericson C, Furberg C. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scand Suppl 1972; 531: 5-9.

5. Sines J, Rothnagel R, van Heel M et al. Electron cryomycroskopy and digital image processing of Lp (a). Chem Phys Lipids 1994; 67/68: 81-89.

6. Marcovina SM, Morriset JD. Structure and metabolism of lipoprotein (a). Curr Opin in Lip 1995; 6: 136-145.

7. Koschinsky ML, Cote GP, Gabel B et al. Identification of the cystein residue in apo (a) that mediates extracellular couping with apo B-100. J Bioch 1993; 268: 1819-1825.

8. Hixson JE, Britten ML, Manis GS et al. Apolipoprotein (a) isoform result from size differences in apo (a) mRNA in baboons. J Biol Chem 1989; 264: 6013-6016.

9. Morrisett JD, Gaubatz JW, Knapp RD et al. Structural propiertis of apo (a): a major apoprotein of human lipoprotein (a). In lipoprotein (a) edited by Scanu A. San Diego: Academic Press Ic., 1990: 53-74.

10. Lackner C, Cohen JC, Hobs HH. Molecular definition of the extreme size polymorphism in apolipoprotein (a). Hum Mol Genet 1993; 2: 933-940.

11. Eaton DL, Fless GM. Partial amino acid seguence of apo (a) shows that it homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.

12. White AL, Hixson JE. Molecular basis for null Lp (a) phenotyps and influence of apo (a) size on plasma Lp (a) level in the baboon. J Biol Chem 2000; 269: 28716-28723.

13. Lackner C, Boerwinkle E, Leffert C et al. Molecular vasis of apo (a) isoform size heterogenity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 2153-2161.

14. Boerwickle E. Genetics of plasma lipoprotein (a) concentrations. Current Opinion in Lipidology 1992; 3: 128-136.

15. Krempler F, Kostner GM, Bolzano K. Turnover of lipoprotein (a) in man. J Clin Invest 1980; 62: 1483-1490.

16. Kraft HG, Menzel HJ. Changes of genetics apolipoprotein phenotypes caused by liver transplantation: Coplication for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-142.

17. Hobbs HH, Whute AL. Lipoprotein (a): intrigues and insights. Current Opinion in Lipidology 1999; 10: 225-236.

18. Argaves KM, Korzansky KF. The aterogenic Lp (a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100: 2170-2182.

19. Parra HJ, Mezdour H, Cachera C. Lp (a) lipoprotein in patients with chronical renal failure treated by hemodialysis. Clin Chem 1987; 33: 721.

20. Yhigszi AAR, Lavi E, Bdeir BR et al. Defensin stimulated the binding of Lp (a) to human vascular endothelial and smooth muscle cells. Blood 1997; 12: 4290-4298.

21. Philips ML, Lembertas AV et al. Physical properties of recombinant apo (a) and its association with LDL to form an Lp (a)-like complex. Biochem 1993; 32: 3722-3728.

22. Yano Y, Shimokawa K, Okada Y et al. Immunolocalizacion of lp (a) in wounded tissues. J Histochem Cytochem 1997; 45: 559-568.

23. Baggio G, Donazzan S, Monti D et al. Lp (a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factor. FASEB J 1998; 12: 433-437.

24. Marcovina SM, Alberts JJ, Wijsman E et al. Differences in Lp (a) concentrations and apo (a) polymorphysm between Black a White Americans. J Lip Res 1996; 37: 2569-2585.

25. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of trasforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113: 1439-1445.

26. Heberland ME, Fless GM, Scanu AM et al. Malondialdehyde modification of liporpotein (a) procedurs avid uptake by human monocytomacrophages. J Biol Chem 1992; 267: 4143-4151.

27. Nacman RL. Trombosis and atherogenesis, molecular connections. Circulation 1992; 96: 2485-2487.

28. Hajjar KA, Nachman RL. The role of Lp (a) in aterogenesis and trombosis. Ann Rev Med 1996; 47: 423-442.

29. Cooke JP. The pathophysiology of periferal arterial disease: rational targets for drug interven. Vasc Med 1997; 2: 227-230.

30. Seman LJ, DeLuca C, Jener JL et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham heart Study. Clin Chem 1999; 45: 1039-1046.

31. Milionis HJ, Winder AF, Mikhailidis DP. Lp (a) and stroke. J Clin Pathol 2000; 53: 487-496.

32. Miner SE, Hegele RA, Sparkes J et al. Homocystein, Lp (a) levels and restenosis after PTCA: a prospective study. Am Heart J 2000; 140: 272-278.

33. von Depka M, Nowak-Gottl U, Eisert R et al. Increased lipoprotein (a) levels as an indipendent risk factor for venous tromboembolism. Blood 2000; 96: 3364-3368.

34. Bo A. Therapy for lowering lipoprotein (a) levels. Curr Opin in Lipid 1997; 8: 337-341.

35. Seed M, O´Conner B. The effect of nicotin acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101: 61-68.

36. Ramharack R, Spahi MA, Nicka GW et al. Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein (a)-protein and liver apolipoprotein (a) mRNA levels. J Lipids Res 1995; 36: 1294-1304.

37. Galetta F, Sampierto T, Basta G et al. Effects of simvastatin on blood levels of lipoprotein (a). Minerva Med 1995; 86: 299-303.

38. Bambauer R, Schiel R, Keller HE et al. LDL apheresis in the treatment of two patients with coronary heart disease and extremly elevated lipropotein (a) levels. Artific organs 1669; 20: 340-343.

39. Henriksson P, Angelin B, Berglund L. Hormonal regulatulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992; 89: 1166-1171.

40. Armstrong VW, Cremer P, Eberle E et al. The association between serum Lp (a) concentrations and angiografhically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986; 62: 249-257.

41. Berg K, Dahlen G, Borresen AL. Lp (a) phemotypes, other lipoprotein parameters and a family history of coronary heart disease in modele-aged males. Clin Genet 1979; 16: 347-352.

42. Buscaglia P, Gazzaruso C, Garzaniti A et al. Lipoprotein (a), apolipoprotein (a) polymorphism, and insulin treatment in type II diabetes patient. Diabetes Care 1995; 18: 1202-1203.

43. Cremer P, Nagel D, Labrot B et al. Lp (a) is predictor of myocard infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Incest 1994; 24: 444-453.

44. Genest J Jr, Jenner JL, McNamara Jr et al. Prevalence of lipoprotein (a) excess in coronary artery disease. Am J Cardiol 1991; 67: 1039-1045.

45. Marburger C, Hambrecht R, Niebauer J et al. Association between lipoprotein (a) and progresion of coronary artery disease in modele-aged men. Am J Cardiol 1994; 73: 742-746.

46. Moliterno DJ, Jokinen EV, Miserez AR et al. No association between plasma lipoprotein (a) concentration and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Tromb BASF Biol 1995; 15: 850-855.

47. Nieminen MS, Mattila KJ, Aalto-Setala K et al. Lipoproteins and thein genetic variation in subject with and without angiographycally verifed coronary Artery disease. Arterioscler Tromb 1992; 12: 58-59.

48. Parlavecchia M, Pancaldi A, Taramelli R et al. Evidence that apoliprotein (a) phenotype is a risk factor for coronary artery disease in men < 55 years of age. Am J Cardiol 1994; 74: 346-351.

49. Ridker PM, Hennekers CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction JAMA 1993; 270: 2195-2199.

50. Rosengren A, Wilhelmsen L, Ericsson E et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population Hample of modele aged men. BMJ 1990; 301: 1248-1251.

51. Morrisett JD. The role of lipoprotein (a) in atherosclerosis. Curr Atheroscler Rep 2000; 2: 234-250.

52. Simons LA. Lipoprotein (a): important risk factor or passing fashion? Med J Aust 1993; 158: 512-514.

53. Tamura A, Waranabe T, Mikuriya Y et al. Serum lipoprotein (a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J 1995; 74: 365-369.

54. Watts GF, Mazurkiewicz JC, Tonge K et al. Lipoprotein (a) as a determinant of the Severiny of angiographically defined carotid atherosclerosis. QJM 1995; 88: 321-326.